Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Greater Cannabis (PK) Charts. Click Here for more Greater Cannabis (PK) Charts.](/p.php?pid=staticchart&s=NO%5EGCAN&p=8&t=15)
GammaCan International, Inc. (“GammaCan”
or “the Company”)
(OTCBB: GCAN), a developer of proprietary immunotherapies for the
treatment of melanoma and other cancers, today announced its lead
anti-cancer immunotherapy, VitiGam™, has
received Orphan Drug designation by the U.S. Food and Drug
Administration (FDA) for the treatment of Stage IIB to Stage IV
metastatic melanoma. GammaCan anticipates filing an IND with the FDA for
a Phase I/II clinical trial by year-end, and initiate clinical testing
of VitiGam™ in early 2008.
Orphan Drug designation entitles GammaCan to exclusive marketing rights
in the United States for VitiGam™ for up to
seven years should GammaCan be the first company to receive marketing
approval for this therapeutic drug product. Under the Orphan Drug Act
(ODA), the FDA will not accept or approve other applications from other
sponsors to market an identical medicinal product for the same
therapeutic indication for the seven-year period. In addition, the
designation allows GammaCan to apply for a waiver from the FDA of
certain filing and user fees required by the Prescription Drug User Fee
Act (PDUFA).
Steven Katz, Chairman of the Board and President of GammaCan said, "We
are very encouraged that the FDA has granted VitiGam™
Orphan Drug designation. This will afford GammaCan additional protection
in marketing VitiGam™ once we are granted
approval. This designation highlights the acute need for new therapies
to treat metastatic melanoma.”
Jacob Nusbacher, M.D., Director of Medical and Scientific Affairs,
commenting on this designation said, “We look
forward to working with the FDA as we would like to make VitiGam™
available for all Stage IIB to Stage IV metastatic melanoma patients as
quickly as regulators will allow, particularly since these patients have
very limited available options for treatment.”
About the Orphan Drug Act
The Orphan Drug Act (ODA) provides for granting special status to a
product to treat a rare disease or condition upon request of a sponsor.
The combination of the product and the rare disease or condition must
meet certain criteria. This status is referred to as orphan designation.
Orphan designation qualifies the sponsor of the product for tax credit
and marketing incentives of the ODA. A marketing application for a
prescription drug product that has been designated as a drug for a rare
disease or condition is not subject to a prescription drug user fee
unless the application includes an indication other than the rare
disease or condition.
About GammaCan
GammaCan develops proprietary immunotherapy and related approaches to
treat melanoma and other cancers. GammaCan's platform patented
technology is based on the use of IgGs (gamma-immunoglobulins), a safe,
relatively non-toxic human plasma-derived product used to treat a
variety of immune deficiencies and autoimmune diseases. In cancer,
IgG-based therapies work by strengthening the patient's immune system.
Many experts currently view immunotherapy as a future alternative to
chemotherapy. The Company's lead drug candidate, VitiGam™,
targets Stage lll and Stage lV melanoma for which no effective treatment
currently exists.
For more information about GammaCan, visit www.GammaCan.com.
About VitiGam™
VitiGam™ is a first-in-class IgG-based
anti-cancer immunotherapy being developed for the treatment of Stage III
and Stage IV melanoma. GammaCan is planning to submit its
Investigational New Drug Application (IND) for VitiGam™
to the FDA in the near future. The Company expects to commence human
clinical trials shortly thereafter. VitiGam™
is an IgG-based product manufactured from the plasma of donors with
Vitiligo, a benign skin condition affecting up to 2% of the general
population. Studies have shown that this "enriched" IgG formulation
contains potent anti-melanoma activity. Based on these studies, GammaCan
expects VitiGam™ to provide both, specific
anti-melanoma activity (directed against melanoma cells), and
non-specific anti-cancer activity.
About Melanoma
Melanoma is a deadly form of skin cancer. According to the American
Cancer Society, melanoma accounts for approximately 4% of all skin
cancers but causes approximately 75% of all skin cancer-related deaths.
An estimated 62,000 people will be diagnosed with and nearly 8,000
people will die from melanoma in the U.S. alone in 2007. If rapidly
diagnosed and surgically removed, early-stage melanoma is usually
curable. However, for patients with metastatic melanoma (Stage III and
Stage IV), the prognosis is poor since no effective treatment currently
exists. These patients have a median survival time of 8.5 months and a
5-year survival rate of less than 10%. There has been little change in
these results for in excess of 25 years. The incidence of melanoma has
increased more rapidly than any other cancer during the past 10 years.
The last drug to treat patients with metastatic melanoma was approved by
the FDA over 30 years ago.
Safe Harbor Statement
Statements in this press release that are not purely historical are
forward-looking statements. Forward-looking statements in this press
release include statements regarding: the commercialization of
anti-cancer immunotherapies and the Company's efforts to develop
therapies to boost the immune systems of cancer patients by the use of
IgG-based therapy. Actual outcomes and the Company's actual results
could differ materially from those in such forward-looking statements.
Factors that could cause actual results to differ materially include
risks and uncertainties such as the inability to finance the planned
development of the technology; the inability to hire appropriate staff
to develop the technology; unforeseen technical difficulties in
developing the technology; the inability to obtain regulatory approval
for human use; competitors' therapies proving to be more effective,
cheaper or otherwise preferable for consumers; the inability to market a
product; all of which could, among other things, delay or prevent
product release, as well as other factors expressed from time to time in
GammaCan's periodic filings with the Securities and Exchange Commission
(the "SEC"). As a result, this press release should be read in
conjunction with GammaCan's periodic filings with the SEC, which are
incorporated herein by reference. The forward-looking statements
contained herein are made only as of the date of this press release and
GammaCan undertakes no obligation to publicly update such
forward-looking statements to reflect subsequent events or circumstances.